Page 54 - PRESENTATION
P. 54
PSA Doubling Time
• Progression of CRPC to Patients with shorter PSADT are at greater
bone metastases is risk for bone metastasis or death
common
3.0
• Median survival for men 2.8
with CRPC metastatic to 2.6
bone is ~ 1.5 to 2 years 2.4
• Important to identify who Increasing Risk Relative Risk for Bone Metastasis or Death 2.2
is at greater risk for bone 2.0
metastases 1.8
1.6
1.4
1.2
20 18 16 14 12 10 8 6 4 2 0
PSADT (months)
Shorter PSADT
55 Smith MR et al. J Clin Oncol 2013; 31:3800-3806
